Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.53 |
| ▸ | HTR2A | P28223 | 7/20 | 0.48 |
| ▸ | HTR2B | P41595 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11958228 | 1.00 | HTR2C (0.53) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL11958085 | 1.00 | HTR2C (0.53) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL11980424 | 0.92 | HTR2C (0.49) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL11958220 | 0.92 | HTR2C (0.49) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL13134846 | 0.92 | HTR2C (0.51) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL11958801 | 0.89 | HTR2C (0.46) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL13876599 | 0.89 | HTR2C (0.46) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL11958758 | 0.89 | HTR2C (0.46) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL11958214 | 0.89 | HTR2C (0.46) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 | |
| SCHEMBL10049349 | 0.87 | HTR2C (0.44) | HTR2CHTR2AHTR2BALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819684-B1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INT BV (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | GILBERT ERIC J (US) | 2013-03-21 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100286160-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INC. | 2010-11-11 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| WO-2009005671-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286160-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | HTR2C 22/4885HTR2A 37/4885HTR2B 45/4885 |
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | HTR2C 22/4885HTR2A 37/4885HTR2B 45/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | HTR2C 22/4885HTR2A 37/4885HTR2B 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.